3 / 21
conferenceseries
.com
Volume 8
Journal of Alzheimers Disease & Parkinsonism
Dementia 2018
December 13-15, 2018
Page 22
Notes:
December 13-15, 2018 Abu Dhabi, UAE
13
th
Annual Conference on
Dementia and Alzheimer's Disease
Effects of chronic administration of Memantine on okadaic acid induced spatial short-term memory
impairment
Mariam Chighladze
1
, Manana Dashniani
1
, Maia Burjanadze
1
and Khatuna Rusadze
2
1
Ivane Beritashvili Center of Experimental Biomedicine, Georgia
2
Akaki Tsereteli State University, Georgia
A
lzheimer’s Disease (AD) is a neurodegenerative disease that causes progressive cognitive and behavior impairment in
the elderly. It is widely believed that changes in the cerebral activity of protein phosphatases have been implicated in the
pathogenesis of AD. Okadaic Acid (OA) is a potent and selective inhibitor of protein phosphatases. OA induced memory
deficit and elevation of Ca
2+
was found to be correlated with neurotoxicity and N-Methyl-D-Aspartate (NMDA) receptor
emerged as a plausible link. According to available data, the NMDA receptor antagonists (including memantin) have the
potential to perform neuroprotective role in neurodegenerative processes caused by Ca
2+
ionotoxicity. In the present study, the
possible beneficial effect of memantine on the OA induced spatial short-term memory impairment was examined in spatial
alternation task. OA was dissolved in artificial Cerebro-Spinal Fluid (aCSF) and injected Intra Cerebro Ventriculary (ICV) 200
ng in a volume of 10 μl bilaterally. Vehicle control received aCSF ICV bilaterally. Control and OA injected rats were divided
into two subgroups injected i.p. with saline or memantine (5 mg/kg). Memantine or saline were given daily for 13 days starting
from the day of OA injection. Behavioral study showed that bilateral ICV microinjection of OA induced impairment in spatial
short-term memory and chronic administration of memantine effectively attenuated OA induced spatial short-term memory
impairment. Therefore, ICV injection of OA can be used as an experimental model to study mechanisms of neurodegeneration
and define novel therapeutics targets for AD pathology.
Biography
Mariam Chighladze has completed her PhD from St Andrew the First-Called Georgian University of the Patriarchate of Georgia. She is the Laboratory Assistant at
Ivane Beritashvili Center of Experimental Biomedicine, Laboratory of Behavior and Cognitive Functions. She has published more than four papers.
Mariam Chighladze et al., J Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C8-057